| Gene symbol | RPE65 | Synonyms | BCO3, LCA2, RP20, mRPE65, p63, rd12, sRPE65 | Type of gene | protein-coding |
| Chromosome | 1 | Map location | 1p31.3 | dbXrefs | |
| Description | retinoid isomerohydrolase RPE65 | ||||
| GTO ID | GTC3625 |
| Trial ID | NCT06088992 |
| Disease | Leber Congenital Amaurosis |
| Altered gene | RPE65 |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | HG004 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | An Investigator-Initiated Open-Label, Multiple-Dose Clinical Study to Evaluate the Safety,Tolerability, and Efficacy of Gene Therapy for 2Leber's Congenital Amaurosis With RPE65 Mutation (LCA2) |
| Year | 2023 |
| Country | China |
| Company sponsor | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine |
| Other ID(s) | HG00401 |
| Vector information | |||||||||
|
|||||||||
| Cohort 1 | |||||||
|
|||||||